Zhixiang Jintai: GR2301 injection obtained the drug clinical trial approval notice.

Zhixiang Jintai Announcement: Recently, the company has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The company's clinical trial application for GR2301 injection has been approved. GR2301 injection is a recombinant fully human anti-IL-15 monoclonal antibody developed independently by the company. It can block the binding of IL-15 to IL-15R and IL-15&IL-15R complex to IL-2R&IL-2R complex, inhibit downstream signaling pathway of JAK-STAT, and achieve the effect of treating autoimmune diseases such as vitiligo caused by abnormal expression of IL-15.